Nabi Biopharmaceuticals Altastaph for the Prevention and Treatment of Staph. Aureus Infections
November 17, 2004 by admin · Leave a Comment
On Nov 17, 2004 Nabi Biopharmaceuticals released results from its Phase 2 clinical trial of Altastaph in premature or very low birth weight infants (infants weighing between 500 and 1500 grams). The company indicated that while the primary end-points of the study were met, an unexpectedly low rate of S. aureus infections in both the [...]
VaxGen’s rPA102 Recombinant Anthrax Vaccine
April 15, 2004 by admin · Leave a Comment
On April 15, 2004 VaxGen, Inc. announced that it had started the Phase II clinical testing of rPA102, its recombinant anthrax vaccine. VaxGen indicated that this 13-month trial is one of two studies under a $80.3 million agreement with the NIH’s National Institute of Allergy and Infectious diseases. The purpose of this study, involving 480 [...]